CHPA board and chair
This article was originally published in The Tan Sheet
Lil' Drug Store Products President and CEO Christopher DeWolf takes the helm of the Consumer Healthcare Products Association's board. DeWolf succeeds John Hendrickson of Perrigo as chairman, CHPA announces March 14 during its executive conference in Naples, Fla. Joining DeWolf on the board are vice chairmen Timothy Brown, Procter & Gamble's North American Personal Health general manager; Patrick Lonergan, president of NUMARK Laboratories; James Mackey, senior VP of sales and operations of consumer healthcare at Schering-Plough Health Care Products; Jeffrey Needham, senior VP commercial business development with Perrigo; and Cavan Redmond, president of Wyeth Consumer Healthcare
You may also be interested in...
CHPA reelects chair, adds board members: The Consumer Healthcare Products Association 1re-elects Lil' Drug Store Products President and CEO Christopher D. DeWolf as chairman and adds new members to its board. New members include Edward C. Kuehnle, president of Catalina Marketing Corp's marketing services, Diane K. Manwaring, president of Lansinoh Laboratories' North America division, and Robert M. Wengel, the Nielsen Co.'s senior VP of professional services. Also on March 11 at its executive conference in Aventura, Fla., the trade group elected in ex officio capacity Peter N. Stevens, assistant general counsel of GlaxoSmithKline's consumer health care division, as Government Affairs Committee chairman, and Paul J. Weninger, Perrigo VP of consumer health care global quality operations, as Manufacturing Controls Committee chairman. DeWolf was elected to his first one-year term as chairman at CHPA's 2009 executive conference, succeeding Perrigo Executive VP John Hendrickson, who remains a vice chairman (2"The Tan Sheet" March 16, 2009, In Brief)
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.